Results 61 to 70 of about 18,744,545 (170)

Additional file 21 of Validation and test–retest repeatability performance of parametric methods for [11C]UCB-J PET

, 2022
Additional file 21. TRT (%) values estimated for whole brain (grey matter) are presented for each parametric method using 90 minutes data.
Tuncel, Hayel, Boellaard, Ronald, Coomans, Emma M., Hollander-Meeuwsen, Marijke den, de Vries, Erik F. J., Glaudemans, Andor W. J. M., Feltes, Paula Kopschina, García, David Vállez, Verfaillie, Sander C. J., Wolters, Emma E., Sweeney, Steven P., Ryan, J. Michael, Ivarsson, Magnus, Lynch, Berkley A., Schober, Patrick, Scheltens, Philip, Schuit, Robert C., Windhorst, Albert D., De Deyn, Peter P., van Berckel, Bart N. M., Golla, Sandeep S. V.   +20 more
openaire   +1 more source

Cerebrospinal fluid protein elevations in Alzheimer's disease are dissociated from immune cell composition

Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 12, Issue 3, July/September 2026.
Abstract INTRODUCTION Elevated cerebrospinal fluid (CSF) inflammatory proteins have been reported in Alzheimer's disease (AD), yet whether they reflect peripheral immune cell infiltration or central nervous system (CNS)–intrinsic pathological processes remains unclear. We tested whether AD exhibits a distinct CSF protein signature and how it relates to
Sina Zaic, Theresa König, Omar Keritam, Valérie Faber, Katharina Seifried, Sara Silvaieh, Nik Krajnc, Raphael Wurm, Tandis Parvizi, Stefan Macher, Paulus Rommer, Fritz Leutmezer, Gabriel Bsteh, Elisabeth Stögmann, Thomas Berger, Tobias Zrzavy   +15 more
wiley   +1 more source

PET Imaging of Synaptic Density: Challenges and Opportunities of Synaptic Vesicle Glycoprotein 2A PET in Small Animal Imaging

Frontiers in Neuroscience, 2022
The development of novel PET imaging agents for synaptic vesicle glycoprotein 2A (SV2A) allowed for the in vivo detection of synaptic density changes, which are correlated with the progression and severity of a variety of neuropsychiatric diseases. While
Takuya Toyonaga, Arman Fesharaki-Zadeh, Arman Fesharaki-Zadeh, Stephen M. Strittmatter, Stephen M. Strittmatter, Richard E. Carson, Zhengxin Cai   +6 more
doaj   +1 more source

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, Volume 13, Issue 6, Page 1399-1417, June 2026.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes, Daniel G. Di Luca, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Anne S. Bassett   +6 more
wiley   +1 more source

Additional file 2 of Feasibility of imaging synaptic density in the human spinal cord using [11C]UCB-J PET

, 2022
Additional file 2. Automated region of interest definition on mCI PET Images - (A) A single slice of a cropped anatomical CT image. (B) Binarized cropped CT image including voxels including vertebrae. (C) Closed, binarized cropped CT image including vertebrae and spinal cavity. (D) Difference image between (C) and (D) including spinal cavity.
Rossano, Samantha, Toyonaga, Takuya, Bini, Jason, Nabulsi, Nabeel, Ropchan, Jim, Cai, Zhengxin, Huang, Yiyun, Carson, Richard E.   +7 more
openaire   +1 more source

Preclinical PET Studies of [¹¹C]UCB-J Binding in Minipig Brain [PDF]

Purpose: Loss of neuronal synapse function is associated with a number of brain disorders. The [11C]UCB-J positron emission tomography (PET) tracer allows for in vivo examination of synaptic density, as it binds to synaptic vesicle glycoprotein 2A (SV2A)
Thomsen MB, Noer O, Schacht MC, Lillethorup TP, Alstrup AKO, Landau AM, Baerentzen SL, Brooks DJ   +7 more
core   +2 more sources

Relationship between tau and SV2A in the neurotypical population and translation to the Down syndrome population

Alzheimer's &Dementia, Volume 21, Issue S2, December 2025.
Abstract Background Synaptic density loss has been proposed as a major neuronal mechanism through which cognition degrades in Alzheimer's disease (AD). PET imaging studies have observed synaptic density change across the AD continuum using SV2A radiotracer [11C]UCB‐J.
Max McLachlan, Alexandra H DiFilippo, Brecca Bettcher, Lisette LeMerise, Andrew K McVea, Matthew D Zammit, Sigan L Hartley, Barbara B. Bendlin, Bradley T Christian   +8 more
wiley   +2 more sources

SDI-118, a novel procognitive SV2A modulator: First-in-human randomized controlled trial including PET/fMRI assessment of target engagement

Frontiers in Pharmacology, 2023
Background: Current treatments for progressive neurodegenerative disorders characterized by cognitive impairment either have limited efficacy or are lacking altogether.
Wouter Botermans, Michel Koole, Koen Van Laere, Jonathan R. Savidge, John A. Kemp, Stefan Sunaert, Maeve M. Duffy, Steven Ramael, Andrea M. Cesura, Kevin D’Ostilio, Denis Gossen, Torsten M. Madsen, Thomas Lodeweyckx, Jan de Hoon   +13 more
doaj   +1 more source

Synaptic density imaging in behavioral variant frontotemporal dementia: A comparison of 18F‐SynVesT‐1 and 18F‐FDG PET

Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.
Abstract INTRODUCTION Synapse loss, a key feature of behavioral variant frontotemporal dementia (bvFTD), can now be visualized in vivo using positron emission tomography (PET) that targets synaptic vesicle glycoprotein 2A (SV2A). Comparing this new imaging method with the clinical standard of glucose metabolism using 18F‐fluorodeocyglucose (18F‐FDG ...
Arman Fesharaki‐Zadeh, Salih Cayir, Waleed Ibrahim, Yanghong Yang, Jean‐Dominique Gallezot, Mika Naganawa, Yanjun Wu, Takuya Toyonaga, Faranak Ebrahimian Sadabad, Ryan O'Dell, Brian Pittman, Nabeel Nabulsi, Stephen Strittmatter, Richard E. Carson, Yiyun Huang, Christopher H. van Dyck, Adam P. Mecca, David Matuskey   +17 more
wiley   +1 more source

Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine Scale

Annals of Neurology, Volume 99, Issue 4, Page 949-963, April 2026.
Objective Dopaminergic imaging is a key biomarker for both the investigation of the biology of Parkinson's disease and related synucleinopathies and the evaluation of potential therapies in clinical trials. This work presents a harmonized approach for quantifying dopaminergic molecular imaging tracers, such as [123I]ioflupane (dopamine transporter scan
Zhen Fan, Graham Searle, Gaia Rizzo, Justin Albani, Patrick Cella, Robert Comley, Gregory Klein, Luca Passamonti, Cristian Salinas, Adam J. Schwarz, Leonardo Iaccarino, Gilles Tamagnan, Jamie Eberling, Ken Marek, John Seibyl, Roger N. Gunn, The Parkinson's Progression Markers Initiative, Kenneth Marek, Caroline Tanner, Tanya Simuni, Andrew Siderowf, Douglas Galasko, Lana Chahine, Christopher Coffey, Kalpana Merchant, Kathleen Poston, Roseanne Dobkin, Tatiana Foroud, Brit Mollenhauer, Dan Weintraub, Ethan Brown, Karl Kieburtz, Mark Frasier, Todd Sherer, Sohini Chowdhury, Roy Alcalay, Aleksandar Videnovic, Duygu Tosun‐Turgut, Werner Poewe, Susan Bressman, Jan Hammer, Raymond James, Ekemini Riley, John Seibyl, Leslie Shaw, David Standaert, Sneha Mantri, Nabila Dahodwala, Michael Schwarzschild, Connie Marras, Hubert Fernandez, Ira Shoulson, Helen Rowbotham, Paola Casalin, Claudia Trenkwalder, Todd Sherer, Sohini Chowdhury, Mark Frasier, Jamie Eberling, Katie Kopil, Alyssa O'Grady, Maggie McGuire Kuhl, Leslie Kirsch, Tawny Willson, Charles Adler, Roy Alcalay, Amy Amara, Paolo Barone, Bastiaan Bloem, Susan Bressman, Kathrin Brockmann, Norbert Brüggemann, Lana Chahine, Kelvin Chou, Nabila Dahodwala, Alberto Espay, Stewart Factor, Hubert Fernandez, Michelle Fullard, Douglas Galasko, Robert Hauser, Penelope Hogarth, Shu‐Ching Hu, Michele Hu, Stuart Isaacson, Christine Klein, Rejko Krueger, Mark Lew, Zoltan Mari, Connie Marras, Maria Jose Martí, Nikolaus McFarland, Tiago Mestre, Brit Mollenhauer, Emile Moukheiber, Alastair Noyce, Njideka Okubadejo, Sarah O'Shea, Rajesh Pahwa, Nicola Pavese, Werner Poewe, Ron Postuma, Giulietta Riboldi, Lauren Ruffrage, Javier Ruiz Martinez, David Russell, Marie H Saint‐Hilaire, Neil Santos, Wesley Schlett47, Ruth Schneider, Holly Shill, David Shprecher, Tanya Simuni, David Standaert, Leonidas Stefanis, Yen Tai, Caroline Tanner, Arjun Tarakad, Eduardo Tolosa PhD34, Aleksandar Videnovic, Susan Ainscough, Courtney Blair, Erica Botting, Isabella Chung, Kelly Clark, Ioana Croitoru, Kelly DeLano, Iris Egner, Fahrial Esha, May Eshel, Frank Ferrari, Victoria Kate Foster, Alicia Garrido, Madita Grümmer, Bethzaida Herrera, Ella Hilt, Chloe Huntzinger, Raymond James, Farah Kausar, Christos Koros, Yara Krasowski60, Dustin Le, Ying Liu, Taina M. Marques, Helen Mejia Santana, Sherri Mosovsky, Jennifer Mule, Philip Ng, Lauren O'Brien, Abiola Ogunleye, Oluwadamilola Ojo, Obi Onyinanya, Lisbeth Pennente, Romina Perrotti, Michael Pileggi, Ashwini Ramachandran, Deborah Raymond, Jamil Razzaque, Shawna Reddie, Kori Ribb, Kyle Rizer, Janelle Rodriguez, Stephanie Roman, Clarissa Sanchez, Cristina Simonet, Anisha Singh, Elisabeth Sittig, Barbara Sommerfeld, Angela Stovall, Bobbie Stubbeman, Alejandra Valenzuela, Catherine Wandell, Diana Willeke, Karen Williams, Dilinuer Wubuli   +174 more
wiley   +1 more source